The speaker comments on the deepening technical outlook and ideal buying zones of the company, a representative of the healthcare sector.

The speaker analyzes the positioning of global funds like BlackRock in specific stocks in Borsa Istanbul.

The expert evaluates Medical Park's stock as one of the key companies in his model portfolio. He examines the company's expectations for significant increases in EBITDA margins, improvements in operational expenses, and the upward trend in its technical outlook.

Analysts address growth expectations in the healthcare sector and the stock's place in model portfolios along with target prices.

The speaker examines the position and valuation potential of the healthcare company in two different model portfolios.

The speaker interprets the recent performance of the healthcare stock and suitable cost zones for new purchases.

The speaker analyzes the potential correction move to the 340-345 TRY band and accumulation opportunities that may arise at these levels. He interprets the increase in the price score.

The speaker conveys that Medical Park stock has been added to the model portfolio in parallel with the strong outlook in the healthcare sector.

The speaker evaluates the company's new oncology hospital investment and its impact on stock performance.

The speaker, based on the Deniz Investment report, addresses the company's real growth dynamics and success in cost management. It is conveyed that the target price has been revised upwards and the "Buy" recommendation is maintained.

The speaker scrutinizes fund changes on the clearing side by analyzing the company's growth ratios and price score.

Analysis is not available.